Novartis Cell & Gene Therapies Unit to close, but it’s not the end for CAR T research
Novartis plans to disband its high-profile cell and gene therapy unit, which was responsible for advancing one of the leading chimeric antigen receptor T cell, or CAR T, therapies for cancer treatment in the pipeline today. The company said it remains strongly committed to ongoing development of its CAR T technologies.
Improving patient recruitment and study design have long been the goals of many life sciences firms and CROs. Last week, Medidata and SHYFT Analytics signaled their intention to address these concerns by announcing a partnership to create a system that would combine data from electronic medical records (EMRs), health claims and data typically gathered in clinical trials. According to Medidata’s Chief Operating Officer, Mike Capone, this approach would give clients a more complete picture of patient populations and “support efforts to design and execute more effective studies and more efficiently recruit patients for clinical trials.”
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.